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To the Editor—We proposed human challenge trials (HCTs) as a possible alternative or 
complementary to conventional Phase 3 trials for expedited SARS-Cov-2 vaccine efficacy testing 
[1]. Hasford [2] argues that a large, simple, randomized trial, as proposed by Yusuf et al [3], 
could work better. We note that the latter design is similar to that implemented by the WHO 
for the SOLIDARITY platform trial [4]. If vaccine efficacy can be assessed rapidly in such trials 
then HCTs might prove unnecessary, but preparing for HCTs would still be a valuable hedge 
against the possibility of too low an incidence of COVID-19 in field trials in such a fluid situation.   
 
Spinola et al argue that HCTs are generally limited to diseases which can be fully treated. We 
recognize that SARS-CoV-2 is not in that category, but have explained elsewhere why the risks 
remain tolerable [5, 6]. We note also that , since we wrote our original paper, two specific 
therapies have been shown to reduce the risks to patients hospitalised with COVID-19 [7, 8],  
and it is possible that further treatments will be developed in the coming months that reduce 
the risks even further. It is true that we necessarily have no information on the long-term 
outcomes associated with SARS-CoV-2 infections. The informed consent statement must 
include specification that there may be long-term effects of which we are currently unaware. As 
we explained elsewhere, this in no way invalidates participants’ informed consent [9]. Nor does 
the uncertainty otherwise make the trials impermissible [10]. We agree with Spinola et al that 
such trials should not target minority groups for recruitment [5].  
 
Spinola et al argue that “it is unlikely that a SARS-CoV-2 model could be ready to evaluate 
vaccines for years.” But the circumstances of the COVID-19 pandemic have changed the 
paradigm for the time it takes to develop and test new vaccines. If sufficient resources are 
devoted to developing HCTs for SARS-CoV-2, then we believe they could be available much 
sooner. Of note is the recent report that HCTs might be conducted at Oxford University “by the 
end of this year”.[11]  
 
Spinola et al are also concerned that HCTs would not provide adequate data regarding vaccine 
safety and that, even with a parallel  large short-term safety trial, such testing could not detect 
long-term adverse effects. However, even in the type of conventional phase 3 trial that it is 
hoped might produce efficacy data in 3-6 months sufficient to justify widespread vaccine use 
[4], longer-term adverse effects will remain unknown, and must necessarily be studied in post-
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